Jessica Fye
Stock Analyst at J.P. Morgan
(4.37)
# 1,282
Out of 4,978 analysts
591
Total ratings
54.3%
Success rate
7.1%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Reiterated: Buy | n/a | $247.69 | - | 51 | Sep 15, 2026 | |
| VRTX Vertex Pharmaceuticals | Initiated Coverage: Buy | $530 → $560 | $513.26 | +9.11% | 22 | Sep 11, 2026 | |
| AMRN Amarin Corporation | Initiated Coverage: Sell | $10 → $13 | $13.86 | -6.17% | 11 | Aug 21, 2026 | |
| EBS Emergent BioSolutions | Initiated Coverage: Sell | n/a | $6.75 | - | 14 | Aug 21, 2026 | |
| IMCR Immunocore Holdings | Initiated Coverage: Buy | $50 | $31.62 | +58.15% | 15 | Aug 21, 2026 | |
| MBX MBX Biosciences | Initiated Coverage: Buy | $88 | $61.57 | +42.93% | 4 | Aug 21, 2026 | |
| MRNA Moderna | Reiterated: Sell | $40 → $77 | $145.62 | -47.12% | 24 | Aug 21, 2026 | |
| NKTR Nektar Therapeutics | Initiated Coverage: Hold | $30 → $65 | $67.38 | -3.53% | 32 | Aug 21, 2026 | |
| STOK Stoke Therapeutics | Initiated Coverage: Buy | $25 → $40 | $27.91 | +43.32% | 18 | Aug 21, 2026 | |
| BNTX BioNTech SE | Reiterated: Hold | n/a | $95.83 | - | 32 | Aug 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $33 | $22.71 | +45.31% | 3 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $29 | $20.06 | +44.57% | 18 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $118 | $97.37 | +21.19% | 15 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $179 → $175 | $122.58 | +42.76% | 28 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $76 | $44.84 | +69.49% | 33 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $375 | $239.36 | +56.67% | 28 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $276 | $243.59 | +13.31% | 34 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $110 → $120 | $124.75 | -3.81% | 26 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $60 → $61 | $46.07 | +32.41% | 15 | Jul 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $425 | $348.08 | +22.10% | 14 | Jul 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $685 → $687 | $498.48 | +37.82% | 34 | Jul 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $13 → $12 | $8.43 | +42.35% | 19 | Jul 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $76 → $35 | $17.00 | +105.88% | 13 | Jul 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $23 → $17 | $16.22 | +4.81% | 15 | Jul 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $64.73 | - | 16 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $63 → $65 | $108.44 | -40.06% | 19 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $49.37 | - | 3 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $18 → $14 | $26.24 | n/a | 4 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7 → $5 | $2.02 | n/a | 12 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $19 | $1.73 | n/a | 4 | Mar 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $0.7305 | n/a | 3 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $13 → $7 | $102.49 | n/a | 3 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $94 → $66 | $137.96 | n/a | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | n/a | $9.35 | n/a | 3 | Mar 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $32 → $95 | $12.70 | n/a | 4 | Feb 8, 2018 |
Ascendis Pharma
Sep 15, 2026
Reiterated: Buy
Price Target: n/a
Current: $247.69
Upside: -
Vertex Pharmaceuticals
Sep 11, 2026
Initiated Coverage: Buy
Price Target: $530 → $560
Current: $513.26
Upside: +9.11%
Amarin Corporation
Aug 21, 2026
Initiated Coverage: Sell
Price Target: $10 → $13
Current: $13.86
Upside: -6.17%
Emergent BioSolutions
Aug 21, 2026
Initiated Coverage: Sell
Price Target: n/a
Current: $6.75
Upside: -
Immunocore Holdings
Aug 21, 2026
Initiated Coverage: Buy
Price Target: $50
Current: $31.62
Upside: +58.15%
MBX Biosciences
Aug 21, 2026
Initiated Coverage: Buy
Price Target: $88
Current: $61.57
Upside: +42.93%
Moderna
Aug 21, 2026
Reiterated: Sell
Price Target: $40 → $77
Current: $145.62
Upside: -47.12%
Nektar Therapeutics
Aug 21, 2026
Initiated Coverage: Hold
Price Target: $30 → $65
Current: $67.38
Upside: -3.53%
Stoke Therapeutics
Aug 21, 2026
Initiated Coverage: Buy
Price Target: $25 → $40
Current: $27.91
Upside: +43.32%
BioNTech SE
Aug 19, 2026
Reiterated: Hold
Price Target: n/a
Current: $95.83
Upside: -
Aug 14, 2026
Rated: Buy
Price Target: $33
Current: $22.71
Upside: +45.31%
Aug 11, 2026
Reiterated: Buy
Price Target: $29
Current: $20.06
Upside: +44.57%
Aug 11, 2026
Reiterated: Buy
Price Target: $118
Current: $97.37
Upside: +21.19%
Aug 10, 2026
Rated: Buy
Price Target: $179 → $175
Current: $122.58
Upside: +42.76%
Aug 10, 2026
Rated: Buy
Price Target: $76
Current: $44.84
Upside: +69.49%
Aug 4, 2026
Reiterated: Buy
Price Target: $375
Current: $239.36
Upside: +56.67%
Aug 4, 2026
Rated: Buy
Price Target: $276
Current: $243.59
Upside: +13.31%
Jul 30, 2026
Rated: Hold
Price Target: $110 → $120
Current: $124.75
Upside: -3.81%
Jul 29, 2026
Rated: Hold
Price Target: $60 → $61
Current: $46.07
Upside: +32.41%
Jul 23, 2026
Reiterated: Buy
Price Target: $425
Current: $348.08
Upside: +22.10%
Jul 23, 2026
Reiterated: Buy
Price Target: $685 → $687
Current: $498.48
Upside: +37.82%
Jul 13, 2026
Initiated Coverage: Hold
Price Target: $13 → $12
Current: $8.43
Upside: +42.35%
Jul 13, 2026
Initiated Coverage: Hold
Price Target: $76 → $35
Current: $17.00
Upside: +105.88%
Jul 13, 2026
Reiterated: Hold
Price Target: $23 → $17
Current: $16.22
Upside: +4.81%
Oct 27, 2025
Reiterated: Buy
Price Target: n/a
Current: $64.73
Upside: -
Oct 27, 2025
Reiterated: Hold
Price Target: $63 → $65
Current: $108.44
Upside: -40.06%
Oct 13, 2025
Reiterated: Buy
Price Target: n/a
Current: $49.37
Upside: -
Jun 7, 2022
Reiterated: Hold
Price Target: $18 → $14
Current: $26.24
Upside: n/a
Apr 7, 2022
Reiterated: Hold
Price Target: $7 → $5
Current: $2.02
Upside: n/a
Mar 14, 2022
Reiterated: Buy
Price Target: $20 → $19
Current: $1.73
Upside: n/a
Aug 20, 2021
Downgraded: Sell
Price Target: n/a
Current: $0.7305
Upside: n/a
Aug 3, 2021
Downgraded: Hold
Price Target: $13 → $7
Current: $102.49
Upside: n/a
Apr 6, 2020
Reiterated: Hold
Price Target: $94 → $66
Current: $137.96
Upside: n/a
Mar 19, 2018
Downgraded: Sell
Price Target: n/a
Current: $9.35
Upside: n/a
Feb 8, 2018
Downgraded: Hold
Price Target: $32 → $95
Current: $12.70
Upside: n/a